GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (FRA:CY3) » Definitions » Cash From Other Investing Activities

DMK Pharmaceuticals (FRA:CY3) Cash From Other Investing Activities : €0.24 Mil (TTM As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is DMK Pharmaceuticals Cash From Other Investing Activities?

Cash from other investing activities means the cash received by a company that comes from other investing activities.

DMK Pharmaceuticals's cash from other investing activities for the three months ended in Sep. 2023 was €0.00 Mil. It means DMK Pharmaceuticals received €0.00 Mil from other investing activities. DMK Pharmaceuticals's cash from other investing activities for the trailing twelve months (TTM) ended in Sep. 2023 was €0.24 Mil.


DMK Pharmaceuticals Cash From Other Investing Activities Historical Data

The historical data trend for DMK Pharmaceuticals's Cash From Other Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMK Pharmaceuticals Cash From Other Investing Activities Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash From Other Investing Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.25 3.86

DMK Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash From Other Investing Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 0.23 0.01 - -

DMK Pharmaceuticals Cash From Other Investing Activities Calculation

Cash from other investing activities means the cash received by a company that comes from other investing activities.

Cash From Other Investing Activities for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DMK Pharmaceuticals Cash From Other Investing Activities Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's Cash From Other Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.


DMK Pharmaceuticals (FRA:CY3) Business Description

Industry
Traded in Other Exchanges
Address
11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

DMK Pharmaceuticals (FRA:CY3) Headlines

No Headlines